CKAP2L promotes endometrial cancer progression by suppressing AKT ubiquitination and activating the PI3K/AKT signaling pathway
-
By
-
Min Wei
-
Xuefei Bai
-
Lili Xi
-
Yongxiu Yang
-
May 20, 2026
-
Clinical Scorecard: CKAP2L Enhances Endometrial Cancer Development by Inhibiting AKT Ubiquitination and Activating the PI3K/AKT Pathway
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Patients with endometrial cancer, particularly those diagnosed at advanced stages; specify if early-stage patients are included. |
| Care Setting | |
Key Highlights
- Add a highlight on CKAP2L's potential as a prognostic biomarker.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- Monitor CKAP2L levels as a potential biomarker for EC progression; include follow-up care recommendations.
Risks
Patient & Prescribing Data
CKAP2L may influence treatment outcomes through its role in the PI3K/AKT pathway; provide examples of therapies targeting this pathway.
Clinical Best Practices
- Incorporate specific methods for CKAP2L assessment in the evaluation of EC patients.
Related Resources & Content
